Holen Sie sich die Stockscreener-App
121.04
0.50%
-0.5096
Schlusskurs vom Vortag:
$121.55
Offen:
$121.13
24-Stunden-Volumen:
33,269
Relative Volume:
0.02
Marktkapitalisierung:
$24.21B
Einnahmen:
$5.36B
Nettoeinkommen (Verlust:
$1.43B
KGV:
17.12
EPS:
7.0718
Netto-Cashflow:
$1.42B
1W Leistung:
+0.28%
1M Leistung:
+3.62%
6M Leistung:
+22.36%
1J Leistung:
+52.72%
1-Tages-Spanne:
$120.42
$121.50
1-Wochen-Bereich:
$115.77
$124.57
52-Wochen-Spanne:
$79.33
$132.60
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
121.20 | 23.75B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
527.55 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
809.08 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
864.29 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.51 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
361.98 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2026-02-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-01-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-11-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options - Benzinga
James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition - Benzinga
Incyte Q2 Earnings Call Highlights - Yahoo Finance
INCY Looks 18.3% Overvalued on GF Value™ as Growth Momentum Rema - GuruFocus
Earnings call transcript: Incyte Q2 2026 beats forecasts, lifts guidance - Investing.com
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript - AlphaStreet
Incyte lifts annual revenue forecast after settlement with CMS - Yahoo Finance
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte Q2 Results: Adj. EPS $3.09 Beats Estimate, Sales Rise 37% - scanx.trade
INCY Looks 18.4% Overvalued on GF Value™ as of July 28, 2026 - GuruFocus
Incyte (INCY) Q2 Earnings and Revenues Top Estimates - Yahoo Finance Australia
INCY Looks 18.4% Overvalued on GF Value™ - GuruFocus
INCY Looks 18.4% Overvalued on GF Value™ as Growth Outlook Stren - GuruFocus
Is Incyte Corp (INCY) Worth the Current Valuation After Q2 Earni - GuruFocus
Incyte beats Q2 estimates but stock dips slightly on lowered guidance By Investing.com - Investing.com South Africa
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly - Yahoo Finance
Incyte earnings beat by $1.10, revenue topped estimates - Investing.com
Incyte: Q2 Earnings Snapshot - 10TV
Incyte Revenue Rises 38 Percent to $1.67 Billion in Q2 - Quiver Quantitative
Incyte posts Q2 2026 revenue $1.67B, net income $586M; raises 2026 net sales outlook - TradingView
Incyte (NASDAQ: INCY) lifts 2026 sales outlook after strong Q2 results - Stock Titan
INCY|Incyte Corp|Price:118.880|Chg%:+1.210 - TradingKey
Form 4 Incyte Corporation For: 27 July By Investing.com - Investing.com South Africa
Incyte EVP Michael Morrissey Awarded Stock Options and Performance Shares in Equity Compensation Plan - Kalkine Media
Incyte Grants Heeson Lee Stock Options and Performance Shares Worth Notable Equity Compensation - Kalkine Media
Incyte (NASDAQ: INCY) awards EVP stock options, 8,999 performance shares - Stock Titan
Incyte Corp (INCY) awards options and performance shares to EVP - Stock Titan
INCY Looks 18.8% Overvalued on GF Value™ Heading into Q2 Earnings - GuruFocus
Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incyte Corp (INCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Incyte Corporation stock hits 52-week high at 119.6 USD By Investing.com - Investing.com South Africa
Incyte Corporation stock hits 52-week high at 119.6 USD - Investing.com
Incyte earnings on deck: Can pipeline ease Jakafi concerns? By Investing.com - Investing.com South Africa
Incyte earnings on deck: Can pipeline ease Jakafi concerns? - Investing.com
INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings - ChartMill
What To Expect From Incyte’s (INCY) Q2 Earnings - Yahoo Finance
Incyte Corp (INCY) Balance Sheet - TradingKey
The week in pharma: action, reaction and insight – week to July 24, 2026 - The Pharma Letter
Incyte Corp (INCY) Income Statement - TradingKey
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner? - Yahoo Finance
Incyte stock trades steady as Jakafi revenue supports 2024 outlook - AD HOC NEWS
INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup - ChartMill
INCY Maintained by JP Morgan -- Price Target Raised to $110 - GuruFocus
Incyte Corp (INCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
INCY Maintained by Morgan Stanley -- Price Target Raised to $104 - GuruFocus
Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Incyte stock trades steadily as Jakafi revenue supports oncology pipeline - AD HOC NEWS
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine? - Yahoo Finance
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
Incyte Corp-Aktie (INCY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Mayes Patrick A | EVP & Chief Scientific Officer |
Aug 05 '26 |
Option Exercise |
106.47 |
2,207 |
234,979 |
63,648 |
| Mayes Patrick A | EVP & Chief Scientific Officer |
Aug 05 '26 |
Sale |
123.99 |
2,207 |
273,646 |
61,441 |
1.43%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):